130 related articles for article (PubMed ID: 23496232)
1. Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2.
Han ZX; Wang HM; Jiang G; Du XP; Gao XY; Pei DS
Cancer Biother Radiopharm; 2013 Jun; 28(5):398-405. PubMed ID: 23496232
[TBL] [Abstract][Full Text] [Related]
2. Anti-STMN1 therapy improves sensitivity to antimicrotubule drugs in esophageal squamous cell carcinoma.
Wang S; Akhtar J; Wang Z
Tumour Biol; 2015 Sep; 36(10):7797-806. PubMed ID: 25944168
[TBL] [Abstract][Full Text] [Related]
3. Regulation of Oncoprotein 18/Stathmin Signaling by ERK Concerns the Resistance to Taxol in Nonsmall Cell Lung Cancer Cells.
Lin X; Liao Y; Chen X; Long D; Yu T; Shen F
Cancer Biother Radiopharm; 2016 Mar; 31(2):37-43. PubMed ID: 26881937
[TBL] [Abstract][Full Text] [Related]
4. Effects of stathmin 1 silencing by siRNA on sensitivity of esophageal cancer cells Eca-109 to paclitaxel.
Zhu HW; Jiang D; Xie ZY; Zhou MH; Sun DY; Zhao YG
Genet Mol Res; 2015 Dec; 14(4):18695-702. PubMed ID: 26782519
[TBL] [Abstract][Full Text] [Related]
5. High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma.
Bao P; Yokobori T; Altan B; Iijima M; Azuma Y; Onozato R; Yajima T; Watanabe A; Mogi A; Shimizu K; Nagashima T; Ohtaki Y; Obayashi K; Nakazawa S; Bai T; Kawabata-Iwakawa R; Asao T; Kaira K; Nishiyama M; Kuwano H
Ann Surg Oncol; 2017 Dec; 24(13):4017-4024. PubMed ID: 28933054
[TBL] [Abstract][Full Text] [Related]
6. Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: a novel synergistic therapeutic intervention.
Mitra M; Kandalam M; Sundaram CS; Verma RS; Maheswari UK; Swaminathan S; Krishnakumar S
Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5441-8. PubMed ID: 21546534
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of RhoGDIα induces apoptosis and increases lung cancer cell chemosensitivity to paclitaxel.
Rong F; Li W; Chen K; Li DM; Duan WM; Feng YZ; Li F; Zhou XW; Fan SJ; Liu Y; Tao M
Neoplasma; 2012; 59(5):541-50. PubMed ID: 22668020
[TBL] [Abstract][Full Text] [Related]
8. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma.
Chen YL; Uen YH; Li CF; Horng KC; Chen LR; Wu WR; Tseng HY; Huang HY; Wu LC; Shiue YL
Ann Surg Oncol; 2013 Nov; 20(12):4041-54. PubMed ID: 22911364
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition and apoptosis of human B-cell lymphoma in vitro and in vivo by Bcl-2 short hairpin RNA.
Liu Y; Shen Y; Qin C; Shi Y; Rong G; Yu X
Oncol Rep; 2013 Jan; 29(1):244-52. PubMed ID: 23076380
[TBL] [Abstract][Full Text] [Related]
10. Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.
Yu H; Xu Z; Chen X; Xu L; Yin Q; Zhang Z; Li Y
Macromol Biosci; 2014 Jan; 14(1):100-9. PubMed ID: 23966347
[TBL] [Abstract][Full Text] [Related]
11. Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel.
Losert D; Pratscher B; Soutschek J; Geick A; Vornlocher HP; Müller M; Wacheck V
Anticancer Drugs; 2007 Aug; 18(7):755-61. PubMed ID: 17581297
[TBL] [Abstract][Full Text] [Related]
12. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells.
Alli E; Yang JM; Ford JM; Hait WN
Mol Pharmacol; 2007 May; 71(5):1233-40. PubMed ID: 17272681
[TBL] [Abstract][Full Text] [Related]
13. TTP mediates cisplatin-induced apoptosis of head and neck cancer cells by down-regulating the expression of Bcl-2.
Park SB; Lee JH; Jeong WW; Kim YH; Cha HJ; Joe Y; Chung HT; Cho WJ; Do JW; Lee BJ; Park JW; Ko BK
J Chemother; 2015 Jun; 27(3):174-80. PubMed ID: 25604244
[TBL] [Abstract][Full Text] [Related]
14. A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells.
Wu Y; Tang M; Wu Y; Weng X; Yang L; Xu W; Yi W; Gao J; Bode AM; Dong Z; Cao Y
Cell Oncol (Dordr); 2014 Feb; 37(1):53-67. PubMed ID: 24306928
[TBL] [Abstract][Full Text] [Related]
15. Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer.
Guo L; Zhou Y; Sun Y; Zhang F
Eur J Cancer; 2010 Feb; 46(3):636-41. PubMed ID: 20004564
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-9 inhibits vasculogenic mimicry of glioma cell lines by suppressing Stathmin expression.
Song Y; Mu L; Han X; Li Q; Dong B; Li H; Liu X
J Neurooncol; 2013 Dec; 115(3):381-90. PubMed ID: 24043603
[TBL] [Abstract][Full Text] [Related]
17. Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma.
Watanabe A; Suzuki H; Yokobori T; Tsukagoshi M; Altan B; Kubo N; Suzuki S; Araki K; Wada S; Kashiwabara K; Hosouchi Y; Kuwano H
Cancer Sci; 2014 Jun; 105(6):690-6. PubMed ID: 24708177
[TBL] [Abstract][Full Text] [Related]
18. [The effect of Bcl-2 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs].
Wang JQ; Du ZW; Gao XF; Wu M; Zhang YC; Pan Y; Wang Q; Zhang GZ
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):191-7. PubMed ID: 23856142
[TBL] [Abstract][Full Text] [Related]
19. Silencing stathmin-modulating efficiency of chemotherapy for esophageal squamous cell cancer with paclitaxel.
Feng W; Xiaoyan X; Xuan Y; Xiangke L; Zichang Y; Ran Z; Liuxing W; Qingxia F
Cancer Gene Ther; 2015 Apr; 22(3):115-21. PubMed ID: 25572118
[TBL] [Abstract][Full Text] [Related]
20. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway.
Chang MC; Chen CA; Hsieh CY; Lee CN; Su YN; Hu YH; Cheng WF
Biochem J; 2009 Dec; 424(3):449-58. PubMed ID: 19747165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
